More MS news articles for Sep 2001

Early Trial Results of Teva's Oral MS Drug Disappointing

NEW YORK (Reuters Health) Sept 17 - Israeli drugmaker Teva Pharmaceutical Industries Ltd. on Monday announced that interim clinical trial results on an oral formulation of the company's approved injectable multiple sclerosis (MS) drug Copaxone (glatiramer acetate) has failed to achieve statistical endpoints.

In early morning trading on the NASDAQ, shares of Teva dropped 5.98 to 61.07, a decline of almost 9%.

According to Teva, an independent Data Safety Monitoring Committee (DSMC) has recommended that the trial still continue to completion, expected by October, due to the favorable safety profile of the drug. Henry McFarland, chairman of the DSMC, noted, however, that there was little chance that the final results of the study would differ from the interim results.

Although disappointed, Teva executives said during a Monday morning conference call that they intend to continue pursuing an oral MS treatment.

They added that since the early results of the oral Copaxone trial showed a trend for a treatment effect in favor of the higher dose, future studies of the oral formulation are expected to use much higher doses.

Copyright © 2001 Reuters Ltd